Akston Biosciences and OKAVA Pharmaceuticals are testing experimental GLP-1 weight-loss treatments to combat feline obesity.
Akston Biosciences is sponsoring a Cornell University clinical study to evaluate a once-weekly GLP-1 therapy for overweight and obese cats. This research aims to address feline obesity, which Todd Zion, CEO of Akston Biosciences, described as one of the most common yet least effectively treated health issues in veterinary medicine. Simultaneously, OKAVA Pharmaceuticals is conducting the "MEOW-1" trial, testing a long-acting implant designed to deliver medication continuously for up to six months. These trials leverage the same drug class that has revolutionized human weight loss, though analysts warn that pet versions may not replicate the exact pricing or market penetration of human drugs. The shift toward "medicalization" reflects a growing trend in the $200 billion U.S. pet economy, where owners are increasingly seeking longevity and therapeutic nutrition. While biotech firms develop these new treatments, major companies like Nestlé are also expanding into "Personalized Health" products. Success for these drugs will depend on affordability for owners as the industry moves toward a more comprehensive healthcare ecosystem for household pets.